New I-MAK report documents how drug manufacturers extend monopoly pricing — costing Medicare and patients billions
Case studies of blockbuster drugs reveal a repeatable playbook of patent strategies that delay competition well beyond original patent terms NEW YORK, NY, UNITED STATES, April 7, 2026 /EINPresswire.com/ -- The Initiative for Medicines, Access …